Auspex Pharmaceuticals Announces SD-1077 Program for the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auspex Pharmaceuticals Announces SD-1077 Program for the Potential Treatment of Parkinson's Disease and Related Movement Disorders

Auspex to Acquire Remaining Worldwide Rights to SD-1077 Through Purchase of Imphar AG

Clinical Proof-Of-Concept Data for SD-1077 Versus Levodopa Expected in 2016

LA JOLLA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX ), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and rare diseases, today announced that it has been developing SD-1077, a deuterium containing levodopa, in collaboration with Imphar AG, a private German-based drug development company, and it has entered into a share purchase agreement to acquire the remaining rights to SD-1077, and related intellectual property, through the acquisition of Imphar AG. Imphar AG had previously granted Auspex exclusive U.S. and select worldwide rights and retained European and additional worldwide rights, all of which will be transferred to Auspex, along with the related intellectual property, pursuant to the share purchase agreement, subject to the satisfaction of customary closing conditions. The research conducted by Imphar was funded in part by a grant from the Michael J. Fox Foundation for Parkinson's Research.

"Moving forward with SD-1077 adds to the strength of our movement disorder pipeline behind our SD-809 lead program," said Pratik Shah, president and chief executive officer, Auspex. "Based on strong preclinical data and scientific principles, we believe that SD-1077 has significant potential to treat this debilitating disorder which currently has limited effective options. We look forward to continuing to work with the scientists at Imphar and expect to advance SD-1077 into clinical development this year and announce proof-of-concept data in 2016."

SD-1077, an investigational new drug for the potential treatment of Parkinson's disease, has been shown in preclinical models to improve the half-life of dopamine in the brain resulting in a prolonged treatment effect. Auspex is advancing SD-1077 through preclinical studies in preparation for initiation of clinical development by the end of 2015. Data from the clinical studies are expected in 2016.

"Auspex and Imphar AG have had a fruitful collaboration," said Dr. Giesbert Alken, founder and chairman, Imphar AG. "We believe Auspex's expertise in neurological diseases, coupled with its strong leadership team, will be able to accelerate SD-1077 clinical development for the benefit of patients living with Parkinson's disease around the world."

Parkinson's disease affects one million people in the United States, and seven to 10 million people worldwide. Levodopa is considered the current gold standard for the symptomatic treatment of Parkinson's disease. However, the short half-life of levodopa results in dosing multiple times daily, as well as the development of dyskinesia, an involuntary and potentially severely debilitating movement disorder, in 30 to 80 percent of patients within a few years of treatment. SD-1077, a selective deuterium substituted form of levodopa, can potentially improve the half-life of the resulting dopamine in the brain and prolong the anti-parkinsonian effect. These properties of SD-1077 may enable less frequent dosing, a reduction in the daily dose of levodopa and a reduction in the development of dyskinesias and other motor complications of Parkinson's disease.

"Extending the clinical benefit provided by levodopa remains a critical need in the treatment of Parkinson's disease," said Robert A. Hauser, M.D., MBA, Director of the Parkinson's Disease and Movement Disorders Center at the University of South Florida. "We need simple, easily administered medications that can be dosed just a few times daily that will provide sustained benefit through the day even as the disease progresses. A deuterium-containing levodopa represents a novel mechanism to extend the benefit of medication-derived dopamine in the brain. This effect has been demonstrated in animal models of Parkinson's disease and, if confirmed in patients, could provide a significant therapeutic advance."

About Auspex Pharmaceuticals

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven pharmacologics. The company's lead product SD-809 is in the final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements. In addition, Auspex is investing in the broad potential of SD-809 for the treatment of other movement disorders, including tardive dyskinesia and tics associated with Tourette syndrome. The company's pipeline also includes SD-560, which is being developed for potentially treating fibrotic conditions, and SD-1077 for the potential treatment of Parkinson's disease. For further information, please visit the company's website www.auspexpharma.com .

Forward-Looking Statements

Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Auspex's ability to successfully complete its ongoing clinical trials and development programs, Auspex's ability to obtain regulatory approval for its product candidates and market penetration and acceptance of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: Auspex's future preclinical studies and clinical trials may not be successful; changes in regulatory requirements in the United States and foreign countries may prevent or significantly delay regulatory approval of Auspex's product candidates; Auspex may change its plans to develop and commercialize its product candidates; the U.S. Food and Drug Administration (FDA) may not agree with Auspex's interpretation of the data from clinical trials of its product candidates; Auspex may decide, or the FDA may require Auspex, to conduct additional clinical trials or to modify Auspex's ongoing clinical trials; Auspex may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Auspex's ability to obtain regulatory approval; the third parties with whom Auspex has partnered for the development of its product candidates and upon whom Auspex relies to conduct its clinical trials and manufacture its product candidates may not perform as expected; Auspex's product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of Auspex's product candidates could delay or prevent regulatory approval or commercialization; Auspex may be unable to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; Auspex's ability to obtain additional financing; and the accuracy of Auspex's estimates regarding expenses, future revenues and capital requirements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Other risks and uncertainties affecting Auspex are described more fully in Auspex's filings with the Securities and Exchange Commission. Auspex undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

For Media: Dan Budwick, Pure Communications, Inc. (973) 271-6085 For Investors: Monique Allaire Lyons, Pure Communications, Inc. (617) 895-9511

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 39

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 232

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 216

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 147

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 0

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 229

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Launch of RM11, a Game-Changer for Creators

Updated Category News Views 451

Introducing RM11: A New Era for Creators RM11 is an innovative digital platform crafted specifically for creators, prioritizing their needs and ensuring they keep more of their hard-earned money. With a comprehensive payout model allowing creators to retain 90% of earnings, RM11 focuses on fostering a vibrant ecosystem where creators thrive without excessive fees or...

Continue Reading
Tyfast Energy Secures Grant to Enhance Lithium-Ion Battery Tech

Updated Category News Views 174

Tyfast Energy Secures Funding for Advanced Battery Development Tyfast Energy, an innovative battery materials company, has achieved a significant milestone by securing a $100,000 grant aimed at enhancing its development of lithium-ion batteries. This funding, provided by the National Science Foundation's Energy Storage Engine, is expected to expedite the advancement of...

Continue Reading
DMG Blockchain Solutions Sets Stage for AI Growth with MOU

Updated Category News Views 285

DMG Blockchain Solutions Expands into Generative AI DMG Blockchain Solutions Inc. has recently made headlines with its agreement to acquire a 10-megawatt prefabricated data center. This significant advancement positions DMG as a key player in the growing field of Generative Artificial Intelligence (Gen AI). The memorandum of understanding (MOU) signifies a strategic step...

Continue Reading
EPAM Systems Achieves Steady Growth in 2024 Financial Results

Updated Category News Views 205

Financial Overview of EPAM Systems for 2024 EPAM Systems, Inc. (NYSE: EPAM), a premier digital transformation and product engineering company, has reported commendable financial results for the fourth quarter and full year of 2024. The company displayed resilience in its growth amid a changing economic landscape, showcasing a 7.9% increase in revenues year-over-year in...

Continue Reading
Carvana Stock Surges After Bullish Power Inflow Indicator

Updated Category News Views 242

Carvana Stock Gains After Bullish Indicator Carvana Co (NYSE: CVNA) experienced an exciting uptick in its stock price following a noteworthy signal known as the Power Inflow. This indicator, closely monitored by traders focused on order flow analytics, reflects significant shifts in buying momentum, particularly from both institutional and retail investors. The Power...

Continue Reading